CD38 and leukemia: Interestingly, Ouabain was shown to be more effective at targeting the CD34+CD38− leukemic stem cell-like population than the CD34+CD38+ leukemia cells [14], which makes this type of compounds an interesting potential anti-LSCs drug candidate.